TY - JOUR
T1 - Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region
AU - Cauffiez, Christelle
AU - Klinzig, Florian
AU - Rat, Emmanuel
AU - Tournel, Gilles
AU - Allorge, Delphine
AU - Chevalier, Dany
AU - Lovecchio, Tonio
AU - Pottier, Nicolas
AU - Colombel, Jean Frédéric
AU - Lhermitte, Michel
AU - D'Halluin, Jean Claude
AU - Broly, Franck
AU - Lo-Guidice, Jean Marc
N1 - Funding Information:
This study was supported by the Centre Hospitalier Régional et Universitaire de Lille, France, the Génopole Lille Nord-Pas de Calais, Région Nord-Pas de Calais (FEDER), France, and by the Société Française de Toxicologie, France. We express thanks to Claudine Bernard (IRCL, U524) for her excellent technical assistance.
PY - 2004/6/15
Y1 - 2004/6/15
N2 - The human cytochrome CYP4F12 has been shown to be active toward inflammatory mediators and exogenous compounds such as antihistaminic drugs. In the present study, we report the first investigation of polymorphisms in the human CYP4F12 gene. A screening for sequence variations in the 5′-flanking region was performed by a Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) strategy, using DNA samples from 53 unrelated French individuals of Caucasian origin. Several polymorphisms were identified, comprising a large deletion located in intron 1 (CYP4F12*v1), two isolated substitutions -402G>A (CYP4F12*v3) and -188 T>C (CYP4F12*v4) and nine combined mutations, -474T>C, -279A>C, -224A>G, -173G>A, -145C>G, -140T>C, -126T>C, -56T>C, and -21T>G (CYP4F12*v2). Considering the nature and location of the polymorphisms characterizing the CYP4F12*v1 and*v2, the functional relevance of those two allelic variants was further examined by transfecting different cell lines with constructs of the related region of the CYP4F12/luciferase reporter gene. Both alleles lead to a significant decrease of CYP4F12 gene expression in HepG2 cell line and, therefore, are likely to determine interindividual differences in CYP4F12 gene expression.
AB - The human cytochrome CYP4F12 has been shown to be active toward inflammatory mediators and exogenous compounds such as antihistaminic drugs. In the present study, we report the first investigation of polymorphisms in the human CYP4F12 gene. A screening for sequence variations in the 5′-flanking region was performed by a Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) strategy, using DNA samples from 53 unrelated French individuals of Caucasian origin. Several polymorphisms were identified, comprising a large deletion located in intron 1 (CYP4F12*v1), two isolated substitutions -402G>A (CYP4F12*v3) and -188 T>C (CYP4F12*v4) and nine combined mutations, -474T>C, -279A>C, -224A>G, -173G>A, -145C>G, -140T>C, -126T>C, -56T>C, and -21T>G (CYP4F12*v2). Considering the nature and location of the polymorphisms characterizing the CYP4F12*v1 and*v2, the functional relevance of those two allelic variants was further examined by transfecting different cell lines with constructs of the related region of the CYP4F12/luciferase reporter gene. Both alleles lead to a significant decrease of CYP4F12 gene expression in HepG2 cell line and, therefore, are likely to determine interindividual differences in CYP4F12 gene expression.
KW - CYP4F12
KW - Genetic polymorphism
KW - Promoter region
KW - Regulation
UR - https://www.scopus.com/pages/publications/2442453525
U2 - 10.1016/j.bcp.2004.02.033
DO - 10.1016/j.bcp.2004.02.033
M3 - Article
C2 - 15163554
AN - SCOPUS:2442453525
SN - 0006-2952
VL - 67
SP - 2231
EP - 2238
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 12
ER -